Showing 101 results for "gut microbiome"

Top 10 MS Stories of 2022

Multiple Sclerosis News Today brought consistent coverage of the latest scientific research, developments in treatment, and clinical trials for multiple sclerosis (MS) throughout 2022. This is a list of the top 10 most-read articles we published this past year, with a brief description of each. We look forward…

Lcn-2 Protein Marks Intestinal Inflammation in MS, Study Shows

People with relapsing-remitting multiple sclerosis (RRMS) have elevated levels of the lipocalin 2 (Lcn-2) protein in their stool samples, a marker for intestinal inflammation, compared with healthy controls, a study demonstrated. Among patients, findings also demonstrated those with high fecal Lcn-2 had changes in their gut microbiome, the collection…

The Supplements of Mice and Men

Roll up, roll up, for all the fun of the fare! I swallow an awful lot of supplements. Have I also swallowed the barkers’ patter? I don’t think so. But I’m more than aware that if something works on mice, then the chances of it working on me are likely…

Expert Voices: Diet and nutrition for people with multiple sclerosis

In this installment of our “Expert Voices” series, Multiple Sclerosis News Today asked registered dietitian Mona Bostick to answer some of your questions related to diet and nutrition for people with multiple sclerosis (MS). Bostick, who has MS, works in private practice in Greensboro, North Carolina, where she helps…

Probiotics Likely To Be of Help With RRMS, Meta-analysis Finds

Probiotic supplements could ease disability, lessen depression, and improve overall health in people with relapsing-remitting multiple sclerosis (MS), according to an analysis of four randomized clinical trials. Physicians working with these patients might recommend “confirmed probiotic supplements” to help manage “MS concerns,” its scientists wrote, while noting that studies…

#ACTRIMS2021 – Dietary Restriction May Limit Severity of MS

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see the latest stories from the conference. Dietary restriction can lessen the severity of multiple sclerosis (MS) by modulating levels of fat-related hormones, new research…

Need to Know: Natural Strategies to Fight MS Inflammation

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question was inspired by the forum topic “Do you know any natural remedies that help fight inflammation?“, from May…

Non-fermentable Fiber Diet Helped Prevent MS in Mice

A diet that incorporates non-fermentable fiber — a common component of a vegetarian diet — during early life can help prevent the onset of autoimmune diseases such as multiple sclerosis (MS), a new study shows. The study, “Dietary non-fermentable fiber prevents autoimmune neurological disease by changing gut metabolic and…

#CMSC16 – Lifestyle Factors and Unconventional Medicine in MS Care

A symposium focused on lifestyle factors and unconventional medicine as part of the clinical care provided to patients with multiple sclerosis (MS) took place today at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC). The symposium, “Expanding the MS Toolkit: Integrating Lifestyle Factors and Unconventional Medicine…

#CMSC16 – Patricia Coyle, an MS Expert, Talks About Vitamin D, Fatigue and Other Key Issues

The Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting began today, June 1. Multiple Sclerosis News Today is providing extensive on-site coverage of the meeting, reporting on presentations, and conducting exclusive interviews with top researchers in the field of multiple sclerosis (MS) and with biopharmaceutical representatives on the latest advances in MS therapies.

Experimental RRMS Therapy, Trimesta, Fails to Demonstrate Efficacy in Review of Clinical Trial

Synthetic Biologics, Inc., a clinical stage company focused on the development of therapeutics to protect the microbiome and to target disease-causing pathogens, recently announced disappointing results from an independent third-party analysis of a Phase 2 clinical trial evaluating Trimesta as a treatment for relapsing-remitting multiple sclerosis (RRMS) in women.

National MS Society Announces $28 Million Funding For Research

The National Multiple Sclerosis Society has announced it will grant $28 million to 84 new research projects and training awards focused on multiple sclerosis (MS). The new financial support is included in the society’s comprehensive research strategy, which was designed to not only end MS, but also restore patients’…